Bariatric surgery takes off more weight than GLP-1 medication: an indirect comparison pooling 30 randomised trials found about 10.3 percentage points more total weight loss with surgery under two years (Sabatella 2026). In Singapore, MediSave can be claimed for bariatric surgery, while MediSave generally does not cover weight-management medication (MOH TOSP 2026; MOH Medisave outpatient). Medication can be stopped, while surgery is a permanent change.

One structural fact governs everything below. Few randomised trials have compared GLP-1 medication with bariatric surgery directly. Every number that looks like a head-to-head result has been assembled indirectly, and the paper that produced the ten-point figure says so in its own words (Sabatella 2026). Weight loss injections in Singapore sets out the GLP-1 injections themselves: what is registered here and how they are given.

Percent total weight loss (%TWL) and percent excess weight loss (%EWL): two different denominators that are constantly mixed up. %TWL is the share of your whole starting weight that has gone. %EWL is the share of the weight above a reference healthy weight that has gone — a smaller denominator, so the number comes out roughly twice as large for the same person. A 43.5% %EWL figure and a 20.9% %TWL figure are not on the same scale.

How much more weight does surgery take off?

About ten percentage points more, on the best pooled estimate available. A 2026 network meta-analysis of 30 randomised trials in 20,015 adults with obesity compared the two classes through lifestyle intervention as a common comparator. Under 104 weeks, surgery was superior on percent total weight loss by 10.3% (p=0.001), on BMI by 4.5 kg/m², on body weight by 11.7 kg and on waist circumference by 12.6 cm. At 104 weeks and beyond, surgery remained superior by 9.1 percentage points of total weight loss (p=0.022) and 14.6 kg of body weight (Sabatella 2026). Individual results vary, and these are trial populations under trial conditions.

The long-run figure comes from the Swedish Obese Subjects study, which followed 2,010 surgical patients and 2,037 matched usual-care controls for two decades. Mean body-weight change was −23% at two years, −17% at ten, −16% at fifteen and −18% at twenty years in the surgical group, against 0%, 1%, −1% and −1% in controls (Sjöström 2013). Two limits matter. SOS was not randomised — patients chose surgery and controls were matched contemporaneously — and its procedure mix is historical: about two-thirds had vertical banded gastroplasty, an operation no longer performed, and only 13% had gastric bypass.

For a modern procedure comparison, the ten-year SLEEVEPASS randomised trial reported a median 43.5% excess-weight loss after sleeve gastrectomy and 50.7% after gastric bypass, a difference of 8.4 percentage points favouring bypass (Salminen 2022). Note the denominator: that is excess-weight loss, not total, and the trial's median baseline BMI was 44.6, well above a typical GLP-1 patient in Singapore.

Routine practice shows a wider gap than the trials do, for a reason worth naming. In a two-centre US cohort of 44,025 adults with BMI 35 or above, intention-to-treat total weight loss at one year was 5.4% on semaglutide, 9.1% on tirzepatide, 24.4% after sleeve gastrectomy and 29.8% after gastric bypass; among those with a full year of continuous medication orders the medication figures were 7.2% and 11.7% (Brown 2026). The medication columns in that study are dominated by people stopping treatment and by sub-maximal dosing. In a separate US cohort of 7,881 patients, 80.8% were on a low maintenance dose (below semaglutide 1.7 mg or tirzepatide 10 mg), and the whole group, including people who stopped, averaged 8.7% weight loss at one year (Gasoyan 2025). Both are observational, both are American, and neither is an efficacy comparison.

How risky is the operation?

Lower than most people assume, on mortality. Pooling 58 studies covering more than 3.6 million patients and 4,707 deaths, perioperative mortality after bariatric surgery was 0.08% — 0.03% for gastric banding, 0.05% for sleeve gastrectomy, 0.09% for both gastric bypass variants and 0.41% for duodenal switch (Robertson 2021). The paper exists specifically to argue that perceived surgical risk is higher than the measured risk, and its own authors note that fewer than 1% of eligible patients have the operation.

Mortality is not the whole risk picture, and the same evidence base says so. SLEEVEPASS recorded reflux oesophagitis in 31% of sleeve patients versus 7% after bypass at ten years, with reoperation in 15.7% and 18.5% respectively (Salminen 2022). Long-term nutritional monitoring after any bariatric procedure is standard, and it is a permanent commitment rather than a recovery period.

What can be claimed in Singapore?

This is the point where the comparison cuts against medication, and stating it is the accurate thing to do.

Bariatric surgery is named on MOH's Table of Surgical Procedures, which the document itself describes as an exhaustive list — anything not listed is not claimable. Six bariatric entries appear: sleeve gastrectomy at table 5B; gastric banding, biliopancreatic diversion with or without duodenal switch, and gastric reduction and bypass at 5C; revision surgery at 6A; and endoscopic sleeve gastroplasty at 3C (MOH TOSP 2026). Being listed means MediSave and MediShield Life can be claimed against a surgical withdrawal limit — currently in the region of $2,660 to $2,770 for tables 5B and 5C under CPF's April 2025 limits — plus daily ward limits. It does not mean the operation is free, fully funded or automatically approved: MediSave is a capped withdrawal from a patient's own account, and clinical eligibility is decided separately.

Weight-management medication generally sits on the other side of that line. Obesity is not one of the 23 conditions in the Chronic Disease Management Programme (MOH Medisave outpatient), and MOH's CDMP Handbook lists weight-loss medication as claimable for obese patients with a covered condition such as diabetes, if clinically indicated, and elsewhere as not claimable (CDMP Handbook). The practical consequence is usually the same: it is paid for out of pocket — cost, eligibility and process: GLP-1 treatment in Singapore sets out what each scheme does and does not cover.

At GetLean the out-of-pocket figure is one monthly fee, from S$288 a month, all-in — consultation, medication, the plan, the reviews and delivery — and the monthly price depends on the dose prescribed. Before that there is a S$20 first video consultation with Dr Quek, and there is no lock-in. Our pricing page sets it out in full.

Who is each option indicated for?

Different BMI thresholds, set in the same MOH document. Singapore's Healthier SG preventive health care protocol gives bariatric-surgery indications for Asian patients as BMI 37.5 kg/m² or above, or 32.5 or above with a condition such as type 2 diabetes, hypertension, a lipid disorder, fatty liver, polycystic ovarian syndrome, obstructive sleep apnoea or metabolic syndrome. Its medication indications sit lower: BMI 30 or above, or 27.5 to 29.9 among Asians with a complication or comorbidity of obesity (MOH BMI Control protocol).

Several scales run in parallel in Singapore and they are easy to confuse. The thresholds above are treatment-indication thresholds from MOH's care protocol. Singapore's national obesity classification is a different scale again — overweight from a BMI of 23 and obesity from 27.5 (HPB–MOH 2016) — and the registered product information for weight-management medication uses the international thresholds of 30, or 27 to under 30 with a comorbidity. Neither of those is GetLean's eligibility criterion. Our criteria are a BMI of 25 or more. Anyone can book the first consultation and Dr Quek decides there whether a GLP-1 medication suits you.

What happens to muscle, in each case?

Both routes cost lean tissue, and in a similar proportion: pooling randomised trials that measured it by scan, fat-free mass made up 33.3% of the weight lost with incretin-based medicines and 34.2% after bariatric surgery (Busk-Cirera 2026).

After bariatric surgery, pooling 59 studies, lean body mass fell by 8.13 kg (95% CI −9.01 to −7.26) at twelve months, fat-free mass by 8.23 kg, and skeletal muscle mass by 3.18 kg. Roughly 55% of the twelve-month lean-body-mass loss happened within the first three months (Nuijten 2022). Those are absolute kilograms in a population starting at a high body weight, not a share of weight lost — and only three of the 59 studies measured skeletal muscle specifically.

On the medication side, the SURMOUNT-1 body-composition sub-study reported that roughly 75% of the weight lost was fat mass and 25% lean mass — and the same ratio held in the placebo arm, which was dieting (Look 2025). The lean-mass share of a large weight loss belongs largely to the size of the weight loss rather than the method, though not entirely: a 2026 meta-analysis found the larger fat-free-mass loss with incretin-based medicines or surgery is not solely explained by larger weight losses (Busk-Cirera 2026).

That comparison is indirect: it pools separate trials of each route, in different people. Surgery took off more fat-free mass in kilograms (−9.1 kg, against −4.8 kg for the medicines measured against placebo), which the authors suggest may reflect the larger weight loss and the higher starting fat-free mass of surgical patients (Busk-Cirera 2026).

Which one can be undone?

This is the axis where the two genuinely differ, and it runs in medication's favour without any claim about which produces a better result.

Bariatric surgery alters anatomy. Sleeve gastrectomy removes a portion of the stomach; bypass reroutes the digestive tract. Revision procedures exist and are themselves TOSP-listed, but the starting position is a permanent change made under general anaesthesia.

Medication can be stopped, which is what makes it reversible, and the withdrawal trials show what taking it away looks like. In the STEP 1 extension, semaglutide and the trial's lifestyle support were stopped at week 68 with no taper; over the following year participants regained 11.6 percentage points of the weight they had lost, about two-thirds of it, and finished 5.6% below their original baseline (Wilding 2022). A planned exit is built around that. At GetLean the taper is planned from the first consultation, the dose is stepped down at Dr Quek's monthly reviews rather than stopped overnight, and the habits that hold the result are built with daily WhatsApp coaching while the medication is still working. Never stop or change a prescribed medicine on your own.

Against that, SOS is the reminder that surgery's durability is real and measured over twenty years, which no medication has been observed for (Sjöström 2013). The published trial figures for GLP-1 medication run to 68 and 72 weeks in the pivotal studies — a mean −14.9% and −20.9% respectively (Wilding 2021; Jastreboff 2022).

What this comparison cannot tell you

Which option suits a particular person is a clinical decision that turns on BMI, comorbidities, surgical risk, prior attempts, and what someone is prepared to commit to permanently. The evidence above compares modalities, not people. If you want to know where you sit against the thresholds, that is a conversation with a doctor — you can start by booking your consult.

The medicines that came before this class were never withdrawn and are still registered here. We compare them in orlistat, phentermine and GLP-1.

Common questions

Which takes off more weight, surgery or GLP-1 medication?

Surgery. Pooling 30 randomised trials through a shared lifestyle comparator, metabolic and bariatric surgery produced about 10.3 percentage points more total weight loss under two years and 9.1 points more beyond two years (Sabatella 2026). Every one of those comparisons is indirect, because few randomised trials have put the two head to head. Individual results vary.

Has anyone run a trial comparing GLP-1 medication against bariatric surgery?

Not in any randomised trial pooled so far. The largest synthesis of the question states plainly that all surgery-versus-medication comparisons in it were indirect, assembled through a shared lifestyle comparator rather than by randomising people to one or the other (Sabatella 2026). A smaller non-randomised trial has compared them directly: at one Chinese hospital, 80 adults chose sleeve gastrectomy or semaglutide (up to 1.5 mg weekly, planned for 24 weeks), and in the 71 analysed, average weight loss at 12 months was 28.6% against 11.3%, with 25 of the 35 on semaglutide having stopped it after six months (Yen 2026).

Can I claim MediSave for weight-loss medication in Singapore?

Generally not. Obesity is not one of the 23 conditions in the Chronic Disease Management Programme (MOH Medisave outpatient), and MOH's CDMP Handbook lists weight-loss medication as claimable for obese patients with a covered condition such as diabetes, if clinically indicated, and elsewhere as not claimable (CDMP Handbook). Bariatric surgery is different: six bariatric procedures are named on MOH's Table of Surgical Procedures, so MediSave and MediShield Life can be claimed for them (MOH TOSP 2026).

How risky is bariatric surgery?

Across 58 studies and more than 3.6 million operations, pooled perioperative mortality was 0.08%, ranging from 0.03% for gastric banding to 0.41% for duodenal switch (Robertson 2021). That figure covers deaths only, not complications, reoperations, reflux or nutritional deficiency, and the meta-analysis was written to argue that surgical risk is commonly over-estimated.

Does bariatric surgery cost muscle?

Yes. Pooling 59 studies, lean body mass fell by about 8.13 kg in the first year after bariatric surgery, with roughly 55% of that loss occurring in the first three months (Nuijten 2022). Those are absolute kilograms rather than a share of weight lost. Pooled across separate randomised trials, fat-free mass made up a similar share of the weight lost after surgery (34.2%) and on incretin-based medicines (33.3%) (Busk-Cirera 2026).